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Abstract
Background: The pathogenesis of diabetes mellitus (DM) is variable, comprising different inflammatory and immune
responses. Proteome analysis holds the promise of delivering insight into the pathophysiological changes associated with
diabetes. Recently, we identified and validated urinary proteomics biomarkers for diabetes. Based on these initial findings,
we aimed to further validate urinary proteomics biomarkers specific for diabetes in general, and particularity associated with
either type 1 (T1D) or type 2 diabetes (T2D).
Methodology/Principal Findings: Therefore, the low-molecular-weight urinary proteome of 902 subjects from 10 different
centers, 315 controls and 587 patients with T1D (n=299) or T2D (n=288), was analyzed using capillary-electrophoresis
mass-spectrometry. The 261 urinary biomarkers (100 were sequenced) previously discovered in 205 subjects were validated
in an additional 697 subjects to distinguish DM subjects (n=382) from control subjects (n=315) with 94% (95% CI: 92–95)
accuracy in this study. To identify biomarkers that differentiate T1D from T2D, a subset of normoalbuminuric patients with
T1D (n=68) and T2D (n=42) was employed, enabling identification of 131 biomarker candidates (40 were sequenced)
differentially regulated between T1D and T2D. These biomarkers distinguished T1D from T2D in an independent validation
set of normoalbuminuric patients (n=108) with 88% (95% CI: 81–94%) accuracy, and in patients with impaired renal
function (n=369) with 85% (95% CI: 81–88%) accuracy. Specific collagen fragments were associated with diabetes and type
of diabetes indicating changes in collagen turnover and extracellular matrix as one hallmark of the molecular
pathophysiology of diabetes. Additional biomarkers including inflammatory processes and pro-thrombotic alterations
were observed.
Conclusions/Significance: These findings, based on the largest proteomic study performed to date on subjects with DM,
validate the previously described biomarkers for DM, and pinpoint differences in the urinary proteome of T1D and T2D,
indicating significant differences in extracellular matrix remodeling.
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Diabetes mellitus (DM) is a complex disease characterized by
insufficient insulin production and resultant hyperglycemia with
alterations in fat and protein metabolism. With time these
alterations cause secondary cellular dysfunctions and vascular
damage including diabetic nephropathy, retinopathy, neuropathy,
and macrovascular disease or vascular alterations. The most
common types of DM are type 1 diabetes (T1D) and type 2
diabetes (T2D). T1D is associated with destruction of insulin-
producing b-cells in the islets of Langerhans in the pancreas,
typically by an autoimmune mechanism, leading to insufficient
insulin production. In contrast, T2D is caused by insulin resistance
combined with insufficient insulin synthesis and is often associated
with obesity.
Although all forms of DM are characterized by hyperglycemia
and b-cell dysfunction, the pathogenesis of DM is variable,
comprising different degrees of b-cell dysfunction, apoptosis,
inflammation and immune responses. Proteome analysis holds
the promise of delivering substantial insight into the pathophys-
iological changes associated with different types of DM. Urine
represents an excellent specimen for proteome analysis, as it can
be obtained in high quantities without the need for special
collection procedures [1], shows higher stability than blood [2,3],
and enables the identification of valid biomarkers for renal, as well
as systemic diseases [4,5]. Recently, we identified and validated
urinary proteomics biomarkers for DM, and DM associated
micro- and macrovascular complications [3,6–11]. These bio-
markers also gave indications of relevant pathophysiological
changes: the interference with homeostasis of extracellular matrix
(ECM) turnover [9].
Based on these initial findings, we aimed to further validate
urinary proteomics biomarkers for DM in general, and examine
specific association of urinary proteins and peptides with either
T1D or T2D. The identification of these differences in the urinary
proteome should provide a deeper understanding of the
pathophysiological changes associated with DM, especially DM
associated micro- and macrovascular disease, and may result in
advancements in therapeutic strategies.
Results
A. Urinary biomarkers for DM
Recently, we identified a panel of 261 urinary biomarkers that
exhibit significant differences between patients with DM and non-
DM individuals [11]. In the study by Snell-Bergeon et al. [11], an
SVM-derived classifier based on the DM specific panel (‘‘diabetes
7’’) was tested in a small one-center cohort of patients with T1D.
In this first part of the study (A), to thoroughly validate these
marker candidates in an independent multicenter validation set,
we collected 697 urine samples from patients with either T1D or
T2D and healthy controls in 9 additional centers. Urine samples of
382 DM and 315 non-DM were analyzed using CE-MS urinary
proteome analysis, as graphically outlined in Figure 1A. The
distribution of the 261 biomarkers in the 697 validation samples is
given in Table S1. The established diabetes 7 model enabled
classification of this independent validation cohort with an AUC in
ROC analysis of 94% (95% CI: 92–95%) (Figure 2A). The
comparison of classification scores for the non-DM control
samples showed statistically highly significant differences
(P,0.0001) compared to T1D and as well as to T2D patients
(Figure 2B and Table S2). In order to further validate the
individual DM biomarker candidates, we applied Mann-Whitney
U-testing to identify out of the 261 peptides those which are
significantly associated with DM also in the independent
multicenter cohort of 697 patients. Of the 261 peptides, 148
displayed P#0.05 in the validation cohort, indicating significant
association with DM in this independent patient cohort.
In summary, the previously developed DM specific panel is able to
identify patients with DM independent of the diabetes type.
However, the AUC value of only T1D patients compared to controls
is higher (0.946) than the AUC value of T2D patients (0.932).
Figure 1. Study design. Flow chart describing the selection of samples used in this study. A: Urine samples from 697 individuals were analysed
blinded, those contained 315 apparently healthy controls, and 382 urine samples from diabetic individuals. B: Samples from 587 well-characterized
DM patients were used to identify DM type specific biomarkers. 382/587 samples were used for validation of previously described markers for DM.
doi:10.1371/journal.pone.0013051.g001
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patients and, interestingly, it was significantly (P=0.034) different.
B. Urinary biomarkers distinguishing type 1 and type 2
DM
After successful validation of DM specific biomarkers, and
initiated by the observed difference between T1D and T2D, we
subsequently aimed to investigate these differences in more detail
in this second part of the study (B). For this purpose we employed
the urinary proteome data from the 382 DM subjects described
above and additional urinary proteome data from 205 diabetic
subjects previously used for DM biomarker discovery [11], a total
of 587 datasets from DM subjects (299 T1D and 288 T2D,
Figure 1B).
To avoid any interference of peptides deriving from diabetic
nephropathy,weonlyincludeDMpatientswithoutanyevidencefor
renal disease. Therefore, we used urine samples of normoalbumi-
nuric T1D and T2D patients to identify DM type specific
biomarkers. Of the 587 diabetic subjects, 369 were excluded due
to evidence of chronic renal disease, and 218 had normal renal
function (136 with T1D and 82 with T2D). These 218 subjects were
randomly divided into a discovery set (n=110, 68 T1D and 42
T2D) and an independent validation set (n=108, 68 T1D and 40
T2D, see Figure 1B, flow sheet, and Table 1). Characteristics
of patients inthe discoveryset (n=110), validationset(n=108),and
the remaining patients with DM who had chronic renal impairment
(n=369) aregiveninTable 2, stratifiedby DMtype. Thestatistical
comparison of the single urinary peptides and proteins in the
discovery data set resulted in the tentative identification of 222
potential marker candidates (see Table S3/set I).
The differences of biomarkers in T1D and T2D patient urine
samples may be caused by different pathophysiology of the DM,
but also by differences of other clinical parameters in both cohorts.
For all data sets, T1D subjects were younger, had longer diabetes
duration, lower systolic blood pressure and BMI, and were less
likely to be treated for hypertension (HTN) or dyslipidemia than
patients with T2D. All T1D patients were treated with insulin and
none were treated with oral hypoglycemics, in contrast to T2D
patients. We analysed whether the different variables contributed
to the prediction of diabetes type. Logistic regression can be used
for prediction of the probability of occurrence of an event and
makes use of several predictor variables that may be either
continuous or categorical. Therefore, logistic regression was
utilized to assess if demographic or clinical data, or medication
use differed by DM type. For this analysis the discovery set was
used. The results revealed that the prediction of DM type was not
significantly dependent on gender, urinary albumin, ACR, GFR,
systolic and diastolic blood pressure, BMI, smoking status, TC,
HDL, LDL, TG and medication status. Of all included
parameters, only age and duration of DM were significantly
independently associated with DM type.
To correct the 222 marker candidates for age and duration of
DM related proteomic changes, we performed a non-parametric
analysis of the variances (Kruskall-Wallis test). The analysis
identified 91 peptides significantly correlated with age (see Table
S3/set I), and one peptide correlated with duration of DM, which
was also among the 91 peptides correlated with age. These 91
peptides were excluded from the list of potentially diabetes type-
associated biomarkers.
The remaining 131 age and DM duration independent
candidate biomarkers (Table S3/set II, Figure 3B) were
employed in SVM-based classifier, which was trained as
potentially ‘diabetes type specific polypeptide panel’ (DTspP) in
the discovery set.
Subsequently, DTspP was evaluated in the validation set
(n=108) consisting of 68 normoalbuminuric T1D and 40 T2D
Figure 2. Results for validation of the urinary proteome pattern specific for diabetes. (A) ROC curve for the independent validation set
(n=697). ROC analysis for diagnosis of DM irrespective of diabetes type using a 261 marker panel [11]. An AUC value of 94% was calculated for the
discrimination of case and control groups of the multicenter patient cohort (P,0.0001). (B) Box-and-whisker plots of SVM scores for the classified
patients. Scores for each individual patient of the validation set are given as open black squares. Medians of T1D [median (interquartile range): 20.78
(21.12 to 20.45)] and T2D [20.63 (21.06 to 20.21)] differed significantly (P=0.034).
doi:10.1371/journal.pone.0013051.g002
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ROC analysis resulted in an AUC value of 88% (95%-CI of 81–
94%). Urine samples of both cohorts (discovery and validation set)
were derived from patients without any measurable renal function
loss. To verify if DN could interfere in the discrimination between
T1D and T2D patients, the DTspP was applied to a further cohort
of DM subjects with impaired renal function (n=369). This
classification resulted in an AUC in ROC analysis (Figure 3D)o f
85% (95% CI of 81–88%; classification factors are listed in Table
S2).
To identify those peptides significantly differentiating T1D and
T2D patients in the validation cohort without (n=108) and with
(n=369) renal impairment, we applied Mann-Whitney U-testing
in these cohorts. This held true in the validation set for 70 markers
in the normoalbuminuric patients group and 86 peptides in the
kidney disease cohort. 57 candidates were significant in both
groups (P,0.05) (Table S3/set II).
Sequencing of DM specific and DM type specific
biomarkers
We applied tandem mass spectrometry to obtain peptide
sequences. We successfully obtained sequences for 100 of the
261 DM biomarkers and 40 of 131 DM type specific peptides
(Table S1 and S3/set II). Of the validated 148 DM markers
and the 57 DM type specific biomarkers we were able to identify
56 and 20 peptides, respectively. Table S4 displays sequence and
information on the regulation of the identified and validated
biomarkers for DM. The regulation of these markers in urine of
DM patients and healthy controls is also shown in Figure 4. The
validated and sequenced DM type-specific markers are listed in
Table 3, and their regulation between T1D and T2D patients are
shown in Figure 5.
The majority of the identified biomarkers were fragments of
collagen alpha-1 (I) and (III). In general, collagen fragment levels
were decreased in urine of patients with DM compared to non-
DM subjects (Figure 4A and B), with even further decreased
levels in urine of T2D compared to T1D patients (Figure 5A and
B). Most of these collagen fragments are C-terminal. In contrast,
fragments of fibrinogen alpha and beta were increased in the urine
of patients with DM compared to non-DM subjects (Figure 4C).
Furthermore, fragments of alpha-1-antitrypsin, membrane-associ-
ated progesterone receptor component 1 and uromodulin (for
regulation see Table S4, 4, Table S1 or S3/set II and
Figure 4D, 5C) were among the biomarkers.
Discussion
This study represent the largest proteomic study (with respect to
cohort size) reported to date. Furthermore, this is the first study to
our knowledge which is dealing with the investigation of differences
between the urinary proteome of T1D and T2D patients. In this
work we successfully validated urinary peptides that are specific for
DM in general (part A), and further identified urinary peptides
significantly associated with T1D or T2D (part B). The defined
biomarkers indicate (patho)physiological differences in the extra-
cellular remodeling of T1D and T2D. Due to different etiopathol-
ogies of T1D and T2D, T1D subjects in our study were significantly
younger, and had significantly longer duration of DM. In addition,
all T1D subjects received insulin treatment. All these potential
confounding factors were considered in the statistical analysis, and
peptides which were significantly associated with these factors were
excluded from further examinations.
The most prominent DM associated urinary proteome changes
were a significant reduction of specific collagen alpha-1 (I) and (III)
fragments, and in direct comparison among patients without
Table 1. Patient cohort.
Clinical condition Patients (N) Primary Use Secondary Use
Discovery set 110
Diabetes type 1 with normoalbuminuria 68 Discovery set to develop diabetic type specific markers Training set to develop DTspP
Diabetes type 2 with normoalbuminuria 42 Discovery set to develop diabetic type specific markers Training set to develop DTspP
Validation set 108
Diabetes type 1 with normoalbuminuria 68 Test set to evaluate
DTspP
Diabetes type 2 with normoalbuminuria 40 Test set to evaluate
DTspP
Chronic kidney disease set 369
Diabetes type 1 with various albuminuria states 163 Validation set to evaluate
DTspP
Diabetes type 2 with various albuminuria states 206 Validation set to evaluate
DTspP
Total Type 1 Diabetes 299 125 of 299 as validation set to evaluate diabetes model
Total Type 2 Diabetes 288 257 of 288 as validation set to evaluate diabetes model
Total with diabetes 587
Healthy controls 315 Validation set to evaluate diabetes model
Total 902
Usage of patient cohorts in this study.
Participating centers: (1) University of Glasgow, Glasgow, United Kingdom; (2) University of Erlangen-Nu ¨rnberg, Germany; (3) University of Melbourne, Austin Health,
Heidelberg, Victoria, Australia; (4) University of Colorado Denver, Aurora, Colorado; (5) RD–Ne ´phrologie, Montpellier, France; (6) University of Groningen, The
Netherlands; (7) Steno Diabetes Center, Gentofte, Denmark; (8) Charles University, Prague, Czech Republic; (9) Harvard Medical School, Boston, Massachusetts, (10)
University of Graz, Graz, Austria.
doi:10.1371/journal.pone.0013051.t001
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more pronounced in T2D than in T1D, despite the lower ACR and
higher estimated GFR in T2D patients. This corresponds to the
morphological observation that along with increased b-cell
apoptosis, pancreatic islets from T2D patients contain amyloid
deposits and resulting fibrosis [12,13]. In this context it is worth
mentioning that extracellular matrix (ECM) homeostasis is
maintained by the balance between tissue inhibitor of metallopro-
teinases (TIMP) and matrix metalloproteases (MMP). Decreased
activity of certain MMPs (e.g. MMP-2, -3, and -9), as described in
diabetes [14–16], would account for our finding of decreased
urinary excretion of collagen fragments, since less collagen filaments
would in this case be cleaved from the ECM. Our data support the
hypothesis that physiological degradation of ECM components,
especially collagen fibers, may be disturbed as a result of DM and
this phenomenon would subsequently result in morphologically
observed increased ECM deposits [15–17]. These data indicate a
demand for further research to investigate the detailed relationship
between MMPs/TIMPs/ECM in DM-associated complications in
a systems approach, as recently suggested [18,19].
In addition, the data on the differences in urinary collagen
fragments may indicate that the mechanism of attenuation of
collagen degradation is different in T1D and T2D. In addition to
MMPs, advanced glycemic end products (AGEs) are prominent
candidates possibly responsible for a disturbance in collagen
breakdown and chemical modification of collagen [20,21]. While
we could not find reports indicating significant differences in
protease activity or AGE status between T1D and T2D, both
phenomena have been observed when comparing patients with
diabetes to normal controls [9,22]. Based on the data reported
here, we hypothesize that the underlying molecular changes that
result in vascular damage and fibrosis in diabetes may be different
between T1D and T2D, as indicated by significant differences in
urinary collagen fragments.
Alpha-1-antitrypsin (AAT) is a member of the serpin family, a
major acute phase protein, and a physiological inhibitor of serin
proteases like neutrophil elastase, resulting in a plethora of various
anti-inflammatory and anti-apoptotic effects [23]. Plasma levels
and activity of AAT are reported to be significantly decreased in
DM patients [24–26], while we and others found urinary
fragments of AAT to be significantly increased [27], suggesting
increased degradation and subsequent renal clearance of AAT-
derived peptides in DM. Increased degradation, resulting in
decreased AAT serum levels, would facilitate conversion of
fibrinogen to fibrin by thrombin and release of fibrinogen-alpha
and –beta. This assumption is supported by the observed increase
of urinary fibrinogen-alpha and –beta-chain fragments in diabetics
compared to controls, and consistent with the the significant pro-
thrombotic risk in DM observed by others [28].
Progesterone receptor membrane component 1 (PGRMC1) is a
member of the so-called membrane-associated progesterone
receptors (MAPR) [29]. As an adaptor protein, PGRMC1 was
proposed to be involved in regulating protein interactions,
intracellular signal transduction and/or membrane trafficking
[29]. Interestingly, in the rat, PGRMC1 activation by progester-
one is discussed as an inhibitor of cell respiration and suppressor of
Table 2. Characteristics of patients with diabetes.
Variables Discovery set Validation set Chronic kidney disease set
type 1
(n=68)
type 2
(n=42) P-value1
type 1
(n=68)
type 2
(n=40)
type 1
(n=163)
type 2
(n=206)
Age, years 43611** 6369 0.0082 47613* 62694 6 611** 64611
Sex [m/f] 45/23 24/18 .0.05 42/26* 28/12 85/78** 144/62
Duration of diabetes, years 27610** 1168 0.0008 28612* 11672 9 611** 1569
Urinary albumin,mg/ml 9610* 666 .0.05 968* 563 1876322** 5096790
ACR,mg albumin/mg creatinine 1067* 766 .0.05 1067* 764 2816414** 5156882
GFR, ml/min/1.73 m
2 91622* 101627 .0.05 98629 109651 74630 79640
Systolic blood pressure, mmHg 126617* 136615 .0.05 129616* 136617 130620** 144618
Diastolic blood pressure, mmHg 76697 3 611 .0.05 75697 6 697 5 610* 78611
BMI, kg/m
2 2765** 3065 .0.05 2766* 31672 6 65** 3266
Smoking status [yes/no] 12/56 8/34 .0.05 10/58 11/29 34/129 48/158
TC, mmol/l 4.660.9 4.861.4 .0.05 4.860.8 4.861.1 4.861.0** 4.561.1
HDL, mmol/l 1.560.5 1.460.5 .0.05 1.560.5* 1.360.4 1.660.6** 1.360.4
LDL, mmol/l 2.660.7 2.460.9 .0.05 2.660.7 2.560.9 2.560.8* 2.361.0
TG, mmol/l 1.361.4 2.161.4 .0.05 1.261.2 1.660.7 1.360.8** 2.261.6
Medications [yes/no]:
HTN 25/43** 32/10 .0.05 33/35** 27/13 110/53** 191/15
Dyslipidemia 13/55** 23/19 .0.05 20/48 19/21 60/103** 153/53
Oral hypoglycemics 0/68** 27/15 .0.05 0/68** 22/18 0/163** 131/75
Insulin 68/0** 22/20 .0.05 68/0** 21/19 163/0** 125/81
Data are mean 6 standard deviation. Abbreviations: m, male; f, female; ACR, albumin extraction rate; GFR, glomerular filtration rate; BMI, body mass index; TC, total
cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HTN, hypertension;
*P-value , 0.05,
**P-value ,0.001 for Univariate analysis;
1logistic regression P-value.
doi:10.1371/journal.pone.0013051.t002
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contribute to pregnancy associated changes in glucose homeostasis
in gestational diabetes.
While uromodulin has previously been reported to be decreased
in patients with DM [31–33], we observe the up-regulation of a
uromodulin fragment without a C-terminal arginine residue
(Table 3). This may be a result of increased proteolytic activity
in DM, resulting in decrease of the parental protein, but increase
in degradation products. However, this hypothesis requires further
investigation.
Several approaches aiming at the analysis of differently
regulated proteins in body fluids from patients with T1D and
T2D have been performed [31,34]. One early proteomic
approach using fractionated human serum samples in the context
of T2D and insulin resistance was performed by Zhang et al. [34]
to mine low abundant proteins. When comparing serum from
patients with T2D or insulin resistance to controls’ serum,
haptoglobin was elevated. Also, several other proteins involved
in the inflammatory response, like a-2 macroglobulin, fibrinogen,
complement C3 and C1 inhibitor were altered. Many of the
detected proteins have been connected to DM, such as the acute
phase protein haptoglobin, which has been associated with
cardiovascular and renal complications in T1D [35,36]. However,
we are not aware of any investigation using urine for the analysis
of differences in the proteome of T1D versus T2D.
Our study has some potential limitations. Health-care provider
definitions of diabetes type were used, and although standard
clinical methodology was used by experienced diabetologists, tests
such as T1D-specific auto-antibodies were not performed.
However, any possible misclassification of subjects by diabetes
type would bias our findings toward the null. Additionally, as
expected, the T1D subjects had different clinical and demographic
characteristics compared to the T2D subjects. Therefore, we
adjusted for these differences in the statistical analyses to avoid
introduction of bias. Although we used state-of-the-art tandem
mass spectrometry to identify discovered biomarker candidates by
peptide sequence, we were unable to sequence all biomarker
candidates. Most likely, we have reached the technical limits of
currently available sequencing technology of naturally occurring
peptides [37]. In general, native peptide sequencing is limited by
post-translational modifications, complicating not only peptide ion
fragmentation, but also subsequent database searches [37,38].
Additionally, the proteomics CE-MS technology is able to detect
polypeptides with a high analytical sensitivity [39,40], whereas
tandem mass spectrometry used for sequencing has higher
detection limits [41,42].
Figure 3. Development of diabetes type specific urinary biomarker pattern. (A) Compiled urinary protein profiles of patients with T1D
(n=68) and T2D (n=42) included in the discovery set. Normalized molecular weight (800–20,000 Da) in logarithmic scale is plotted against
normalized migration time (18–45 min). The mean signal intensity of polypeptides is given as peak height. (B) 3-D contour plots of the 131 DM type
specific markers in the T1D and T2D patient cohort with 3x zoom compared to (A). ROC curves for differentiation of T1D and T2D in an independent
validation set of T1D and T2D patients without clinical evidence of renal dysfunction (n=108, AUC: 88%, C) and patients with evidence for renal
dysfunction (n=369, AUC: 85%, D).
doi:10.1371/journal.pone.0013051.g003
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a multicenter cohort, of differences in the urinary proteome of
T1D versus T2D patients with normal renal function, validated
also in those with chronic kidney disease. Future studies should
enable identification of not yet sequenced differentially expressed
peptides and determine how these differences can be exploited for
disease monitoring and therapeutic issues. However, the vast
amount of data reported here and available today clearly suggest
that alterations in the remodeling of extracellular matrix, and
likely in endogenous proteolytic activity, are among the hallmarks
of DM. These pathophysiological changes likely represent
promising targets for pharmacological intervention, aiming
specifically at prevention of diabetes-associated vascular compli-
cations. Further, the alterations in urinary ECM degradation
products show significant differences between T1D and T2D.
Materials and Methods
Patient characteristics and study design
Urine samples were collected as described previously [43], in
agreement with the protocol established by HUPO (www.hupo.
org/research/urine) and EuroKUP (www.eurokup.org). In short,
urine samples were collected using standard operation procedures
and frozen immediately without the addition of any preservatives.
587 patients with either T1D (n=299) or T2D (n=288) were
recruited at 10 different hospital centers in the US, Europe, and
Australia (see Table 1 for details). The diagnosis of T1D and T2D
was based on commonly accepted diagnostic criteria [44]. The
pre-existing diagnosis of T1D and T2D as assigned in each center
was considered as reference-standard for the purpose of compar-
ison with the generated DM-specific urinary polypeptide panels.
205 of the 587 diabetes patients were previously used [11] for
development of DM-specific panel. These remaining 382 DM
samples and additional 315 samples from healthy non-DM
controls were used in this study as an initial step to validate the
DM (yes/no) panel (53% male, mean age6SD, 40610 years)
[45,46] (Figure 1).
Chronic renal impairment was assessed using albumin/
creatinine ratio .30 mg/g, or with a glomerular filtration rate
(GFR) ,60 unit, and scoring negative in a previously published
classification model for chronic kidney disease [47]. The
Cockcroft-Gault method was used to estimate GFR.
Figure 4. Regulation of diabetes peptide markers statistically significant in the multicenter validation set. Given are SwissProt
accession names. (A) Regulation of collagen alpha 1 type I fragments. For two collagen fragments hydroxylated forms were identified (marked with
asterisk *). (B) Regulation of others collagen fragments. (C) Regulation of fibrinogen alpha fragments. (D) Regulation of other identified peptide
fragments.
doi:10.1371/journal.pone.0013051.g004
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A 0.7 mL aliquot of urine was thawed immediately before use
and diluted with 0.7 mL 2 M urea, 10 mM NH4OH containing
0.02% SDS. In order to remove high molecular weight
compounds of urine, samples were filtered using Centrisart
ultracentrifugation filter devices (20 kDa molecular weight cut-
off; Sartorius, Goettingen, Germany) at 3,000 g until 1.1 mL of
filtrate was obtained. Subsequently, filtrate was desalted using a
PD-10 column (GE Healthcare, Sweden) equilibrated in 0.01%
NH4OH in HPLC-grade water. Finally, samples were lyophilized
and stored at 4uC. Shortly before CE-MS analysis, lyophilisates
were resuspended in HPLC-grade water to a final protein
concentration of 0.8 mg/mL as verified by BCA assay (Interchim,
Montlucon, France).
Urinary proteome analysis
CE-MS analysis was performed as described previously [2,40].
By this procedure the average recovery rate in the preparation
procedure was ,85% and the limit of detection was ,1 fmol [40].
Mass resolution was controlled to be above 8,000 enabling
resolution of monoisotopic mass signals for z#6. After charge
deconvolution, mass deviation was ,25 ppm for monoisotopic
resolution and ,100 ppm for unresolved peaks (z.6). The
analytical precision of the set-up was assessed by reproducibility
achieved for repeated measurements of the same replicate and by
the reproducibility achieved for repeated preparations and
measurements of the same urine sample [40]. To ensure high
data consistency, a minimum of 950 peptides/proteins had to be
detected with a minimal MS resolution of 8,000 in a minimal
migration time interval of 10 minutes. By following this set-up,
CE-MS enabled reproducible and robust high-resolution urinary
proteome analysis.
Data processing
Mass spectral ion peaks representing identical molecules at
different charge states were deconvoluted into single masses using
MosaiquesVisu software [48]. For noise filtering, signals with z.1
observed in a minimum of 3 consecutive spectra with a signal-to-
noise ratio of at least 4 were considered. MosaiquesVisu employs a
probabilistic clustering algorithm and uses both isotopic distribu-
tion (for z#6) as well as conjugated masses for charge-state
determination of peptides/proteins. The resulting peak list
Figure 5. Regulation of identified statistically significant peptide markers for diabetes type in the discovery set. Given are SwissProt
accession names. (A) Regulation of collagen alpha 1 (I) fragments. (B) Regulation of other types of collagen fragments. (C) Regulation of uromodulin
fragments.
doi:10.1371/journal.pone.0013051.g005
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TOF-MS data were calibrated utilizing 80 reference masses
exactly determined by Fourier transform ion cyclotron resonance
mass spectrometry (FT-ICR-MS). For calibration, linear regres-
sion is performed. Both capillary electrophoresis (CE)-migration
time and ion signal intensity (amplitude) show variability, mostly
due to different amounts of salt and peptides in the sample and
were consequently normalized. Reference signals of more then
1700 urinary polypeptides were used for CE-time calibration by
local regression [49]. For normalization of analytical and urine
dilution variances, MS signal intensities were normalized relative
to 29 ‘‘housekeeping’’ peptides with small relative standard
deviation. For calibration, local regression is performed [50].
The obtained peak lists characterized each polypeptide by its
molecular mass [Da], normalized CE migration time [min] and
normalized signal intensity. To avoid artifacts (specific individual
peptides) only detected peptides with frequency .20% were
deposited, matched, and annotated in a Microsoft SQL database
allowing further statistical analysis. For clustering, peptides in
different samples were considered identical, if mass deviation was
#50 ppm for small or #75 ppm for larger peptides. Due to
analyte diffusion effects, CE peak widths increase with CE
migration time. In the data clustering process this effect was
considered by linearly increasing cluster widths over the entire
electropherogram (19 min to 45 min) from 2–5%. After calibra-
tion, mean deviation of migration time was controlled to be below
0.35 minutes. All annotated data are available in Table S5C.
Statistical analysis
Patients’ data analysis. Logistic regression (MedCalc
version 8.1.1.0, MedCalc Software, Belgium, www.medcalc.be)
was used to assess if diabetes type might be predicted from clinical
data (Table 2).
Biomarker discovery. Peptides’ P-values were calculated
using the base 10 logarithm transformed intensities and the
Gaussian approximation to the t-distribution. For multiple testing
corrections, P-values were corrected using the false discovery rate
(FDR) procedure introduced by Benjamini and Hochberg [51].
The FDR is the fraction of false positives among all tests declared
significant. FDR was controlled to be #0.05, which means that on
average less than 5% of peptides declared significant are actually
false positives. On the other hand, the other 95% of the
biomarkers were indeed true positives. The approach is reported
to have high statistical power for biomarker discovery in the
situation of differential expression between two samples, when
subjected to two different treatments, such as disease/no disease
[51]. Only proteins that were detected in a diagnostic group of
patients in at least 50% of samples were considered for testing.
The test was implemented as macros in SAS (www.sas.com) and is
part of the multitest R-package (www.bioconductor.org). Non-
parametric Kruskal-Wallis one-way analysis of variances [52]
(MedCalc version 8.1.1.0, MedCalc Software, Belgium, www.
medcalc.be) was used to assess of candidates’ dependency on age-
and DM duration.
Descriptive statistics. Sensitivity, specificity, and 95%
confidence intervals (95% CI) were calculated using receiver
operating characteristic (ROC) plots [53] (MedCalc version
8.1.1.0, MedCalc Software, Belgium, www.medcalc.be). The
receiver operating characteristic curve (ROC) was obtained by
plotting all sensitivity values (true positive fraction) on the y-axis
against their equivalent (1-specificity) values (false positive fraction)
for all available thresholds on the x-axis. The area under the ROC
curve (AUC) provides the single best measure of overall accuracy
independent of any threshold.
Classification
Disease specific protein/peptide patterns were generated using
support vector machine-based (SVM) MosaCluster software [4].
SVM view a data point (proband’s urine sample) as a p-
dimensional vector (p numbers of protein used in the pattern),
and they attempt to separate them with a (p 2 1) dimensional
hyperplane. The hyperplane with the maximal distance from the
hyperplane to the nearest data point is selected. Classification is
performed by determining the Euclidian distance (defined as the
SVM score) of the polypeptides to the (n-1) dimensional maximal
margin hyperplane and the direction of the vector.
Sequencing of peptides
In order to identify the defined biomarkers, we applied MS/MS
peptide sequencing using CE- or liquid chromatography (LC)-
MS/MS analysis including either collision-induced dissociation
(CID) [8,54] or electron transfer dissociation (ETD) [38,55,56].
Obtained MS/MS data were submitted to MASCOT (www.
matrixscience.com) for search against human entries in the MDSB
Protein Database. Accepted parent ion mass deviation was 0.5 Da;
accepted fragment ion mass deviation was 0.7 Da. Hits were
accepted with MASCOT peptide scores of $20. Additionally, ion
coverage was controlled to be related to main spectral fragment
features (b/y or c/z ion series). If necessary, manual de novo
sequencing was performed to confirm the identifications. The
number of basic and neutral polar amino acids of the peptide
sequences was utilized to correlate peptide sequencing data to CE-
MS data, as described [54].
Supporting Information
Table S1 261 DM-specific peptides included in diabetes7 model.
Shown are the protein/peptide identification number in the
dataset (Protein ID), mass (in Da) and normalized migration time
(in min), the p-values [unadjusted using Mann-Withney U-test],
frequency, mean amplitude and standard deviation in the two
groups of the cohort, and the regulation factor by diabetes
compared to healthy controls. In addition, sequences (modified
amino acids: p=hydroxyproline; k= hydroxylysine; m=oxidized
methionine), protein names, start and stop amino acid, Swiss-Prot
entries and accession numbers are given.
Found at: doi:10.1371/journal.pone.0013051.s001 (0.11 MB
XLS)
Table S2 Classification results by application of the models for
diabetes (diabetes 7) and diabetes type (DTspP). In this table
patient IDs of all included patients are listed in combination with
diagnosis, usage in this study, and classification results. For
training set of DTspP total cross validated data are given.
Found at: doi:10.1371/journal.pone.0013051.s002 (0.11 MB
XLS)
Table S3 ‘‘Set II’’: 131 peptides included in DTspP. Shown are
the protein/peptide identification number in the dataset (Protein
ID), mass (in Da) and normalized migration time (in min), the
adjusted P-values using Benjamini-Hochberg (BH) for training
data and unadjusted P-values using Mann-Withney U-test for
validation and CKD cohorts, the frequency, mean amplitude,
standard deviation in the two groups of diabetes in the training set
and in the group of 315 healthy controls, and the regulation factor
for type 1 compared to type 2 and type 1 and 2 diabetes compared
to healthy controls. In addition, sequences (modified amino acids:
p=hydroxyproline; k= hydroxylysine; m=oxidized methionine),
protein names, start and stop aino acid, Swiss-Prot entries and
accession numbers are given.
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XLS)
Table S4 Identified and validated diabetes markers.
Found at: doi:10.1371/journal.pone.0013051.s004 (0.12 MB
DOC)
Table S5 Pivot Table includes all CE-MS data for all samples in
the study. Given are the mass (in Da) and migration time (in min)
of peptides assigned to a certain Protein ID, which is subsequently
utilized as unique identifier in the database. Sample assignment
indicates the unique patient ID. The table lists the amplitudes of
each polypeptide in the individual samples.
Found at: doi:10.1371/journal.pone.0013051.s005 (3.69 MB ZIP)
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